India's Cipla sets sights on Avastin, Herceptin and Enbrel.
Jayaraman
Killugudi
K
D000911:Antibodies, Monoclonal / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001709:Biotechnology / Q000191:economics; D002681:China; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics*; D007194:India; D018124:Receptors, Tumor Necrosis Factor; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068258:Bevacizumab; D000068800:Etanercept; D000068878:Trastuzumab